![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Hepatitis B surface antigen loss rate and safety and discontinuations with pegylated interferon alpha in chronic hepatitis B virus infection, a systematic review
|
|
|
EASL 2023 June 21-24 Vienna>
Vera Gielen1, Amandeep Kaur2, Krishna Kumar2, Saifuddin Kharawala2, Joyeta Das1, Jacob Vincent1, Anadi Mahajan2>
GSK, Brentford, Middlesex, UK; 2Bridge Medical Consulting, London, UK
![0701231](../images/070123/070123-4/0701231.gif)
![0701232](../images/070123/070123-4/0701232.gif)
![0701233](../images/070123/070123-4/0701233.gif)
![0701234](../images/070123/070123-4/0701234.gif)
![0701235](../images/070123/070123-4/0701235.gif)
![0701236](../images/070123/070123-4/0701236.gif)
![0701237](../images/070123/070123-4/0701237.gif)
![0701238](../images/070123/070123-4/0701238.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|